April 27, 2024

Meet Dr. Amado: Leading Cancer Research at Zai Lab

In this episode of the Life Science Success Podcast, I am joined by Dr. Rafael G. Amado, an esteemed leader in oncology research and development, currently serving as the President and Head of Global Oncology at Zai Lab. With a distinguished career...

In this episode of the Life Science Success Podcast, I am joined by Dr. Rafael G.
Amado, an esteemed leader in oncology research and development, currently serving as
the President and Head of Global Oncology at Zai Lab. With a distinguished career
spanning multiple leading biotech firms, Dr. Amado brings a wealth of experience in
gene-engineered cell therapies and innovative cancer treatments.

 

  • Professional Background: Dr. Raphael Amado is currently the president and head of global oncology at Zai Lab. He has a rich background in medicine, starting with his education in Spain, followed by a move to the U.S. where he specialized in Internal Medicine and later Hematology Oncology at the University of California, Los Angeles.

  • Passion for Oncology: Dr. Amado's interest in oncology stems from its complex nature and the multifaceted approach it requires, combining diagnostics, therapeutics, and a detective-like inquiry into patient cases. His career shift towards oncology was influenced by its holistic approach to patient care and his personal drive to solve complex medical puzzles.

  • Research and Development Focus: At Zai Lab, Dr. Amado oversees oncology research and development, focusing on gene-engineered cell therapies among other innovative treatments. He has been involved in significant breakthroughs, such as determining drug inefficacies in patients with certain genetic mutations, which has influenced global regulatory changes in cancer treatment.

  • Corporate and Global Strategy: Under Dr. Amado’s leadership, Zai Lab has approved six drugs in China, with a strong emphasis on addressing grievous illnesses through open innovation. He is instrumental in expanding the company's global reach, aiming to impact a broad patient base internationally by aligning clinical trials and regulatory strategies across diverse geographic locations.

  • Vision and Future Goals: Dr. Amado is committed to advancing drug development that significantly outweighs potential risks with therapeutic benefits. He is driven by a mission to impact oncology treatment on a global scale, with ambitious goals to reach approximately a million patients by 2030 through continuous innovation and strategic drug development.

Please check out our Life Science Success Resources.  You will find tools that will support growing companies and books for authors I have interviewed.  

Rafael Amado, MD

President and Head of Global Oncology Research and Development

Rafael G. Amado, M.D., joined Zai Lab in December 2022 as President, Head of Global Oncology Research and Development, leading and overseeing the company’s global oncology research and development activities.

Prior to joining Zai Lab, Dr. Amado was the Executive Vice President, Head of Research and Development and Chief Medical Officer for Allogene Therapeutics, Inc. Before joining Allogene, Dr. Amado served as President of Research and Development and Chief Medical Officer of Adaptimmune, LLC from August 2018 to July 2019 and as Chief Medical Officer from March 2015 to July 2018. In these roles, he was responsible for directing discovery and clinical development strategy as well as execution activities for several gene-engineered cell therapies, chairing the R&D leadership team and providing medical guidance for pipeline prioritization. Prior to Adaptimmune, Dr. Amado held various roles of increasing responsibility at GlaxoSmithKline from 2008 to 2015, most recently as Senior Vice President and Global Head of Oncology Research and Development, and at Amgen Inc. from 2003 to 2008, where he was last Executive Director of Clinical Research and Global Development in Therapeutic Oncology.

Dr. Amado received an M.D. from the University of Seville School of Medicine in Seville, Spain and completed his internship and residency in Internal Medicine at the Michael Reese Hospital and Medical Center and a fellowship in Hematology / Oncology at UCLA.